Telomerase has emerged as an important primary target in anticancer therapy. It is a
distinctive reverse transcriptase enzyme, which extends the length of telomere at the 3 …

Cancer remains the most serious disease that threatens human health. Molecularly targeted
cancer therapies, specifically small-molecule protein kinase inhibitors, form an important …

Self-optimising flow reactors combine online analysis with evolutionary feedback algorithms
to rapidly achieve optimum conditions. This technique has been applied to the final bond …

In the past 20 years, cancer therapeutics has undergone a paradigm shift away from the
traditional cytotoxic drugs towards the targeting of proteins intimately involved in driving the …

Purpose: Hyper-activation of the HER (erbB) family receptors, HER 1-4, leads to up-
regulation of the three vital signaling pathways: mitogen activated protein kinase …

Secondary resistant mutations in cancer cells arise in response to certain small molecule
inhibitors. These mutations inevitably cause recurrence and often progression to a more …

Epidermal growth factor receptor (EGFR)-activating mutations are critical factors in the
development of EGFR-driven non-small-cell lung cancer (NSCLC), and molecular targeted …

The epidermal growth factor receptor (EGFR) tyrosine kinase is implicated in a large number
of human cancers. Most EGFR inhibitors target the extracellular, growth factor-binding …

In the era of personalized medicine, epidermal growth factor receptor (EGFR) inhibition with
tyrosine kinase inhibitor (TKI) has been a mainstay of treatment for non-small cell lung …

Recent approvals for oncology drugs have seen an increasing proportion directed to specific
genetic targets identified with an associated companion diagnostic test. In addition, there is …